<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885677</url>
  </required_header>
  <id_info>
    <org_study_id>MDT-MORE-CARE</org_study_id>
    <nct_id>NCT00885677</nct_id>
  </id_info>
  <brief_title>MOnitoring REsynchronization deviCes and cARdiac patiEnts</brief_title>
  <acronym>MORE-CARE</acronym>
  <official_title>MOnitoring REsynchronization deviCes and cARdiac patiEnts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare two different strategies of disease management in
      heart failure patients treated with cardiac resynchronization therapy devices

        1. Remote monitoring with CareLink Network System

        2. Standard management of the disease by means of scheduled routine in-patient follow-ups;

      and to demonstrate that the remote monitoring strategy is superior to the standard strategy,
      both in terms of clinical effectiveness and total healthcare system utilization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major cardiovascular adverse events in patients with heart failure treated with cardiac
      resynchronization therapy (CRT-D) represent a big concern to the medical community, as they
      require hospitalizations and may lead to death.

      Subjects with a history of heart failure are counseled regarding the importance of contacting
      their clinicians promptly if they experience any changes or worsening of their condition.

      Acute heart failure episodes with hospitalizations represent one of the most relevant causes
      of health status deterioration for these patients. Moreover, atrial arrhythmias occurrence is
      a big issue, as it increases the risk of heart failure itself, stroke and inappropriate
      shocks. In addition to affecting patient health, hospital admission resulting from these
      complications will impact healthcare costs.

      Latest generations of Medtronic CRT-D devices are equipped with a system that triggers an
      alarm if possible fluid accumulation is detected (OptiVol). This may initiate
      patient-clinician contact before evident cardiac decompensation. Moreover, advanced
      diagnostic capabilities for detecting atrial arrhythmias occurrence and total burden are
      available on such devices.

      Importantly, all these devices are now able to inform physician of these events by remote
      monitoring with CareLink Network parameters, and have the potential of playing a key role in
      patient monitoring.

      Over the last years, interest has been increasing in remote monitoring models for delivering
      care to HF patients, either as telemonitoring (transfer of physiological data through
      telephone or digital cable from home to healthcare provider) or as regular structured
      telephone contacts between patients and healthcare providers, which may or may not include
      data transfer.

      Several studies with relatively large numbers of patients have been published (see table).

      A recent meta-analysis found that remote monitoring programs for patients with chronic HF
      living in the community reduced admissions to hospital and all cause mortality by nearly one
      fifth while improving health related quality of life, but had no significant effect on all
      cause admission to hospital.

      However, none of the published studies considered remote monitoring systems able to provide
      device-detected information on fluid accumulation, AT/AF total burden, arrhythmias occurrence
      and device-related issues in patients treated with CRT-D devices.

      Early intervention may then be a key element in avoiding major cardiovascular events to occur
      and possible deterioration of the disease progression. The Carelink Network remote monitoring
      system, through Care Alerts, may initiate subject-clinician contact before typical signs and
      symptoms are exhibited, since it provides the physician with an automatic alert for atrial
      arrhythmias occurrence, fluid accumulation, and system integrity issues. However, clinical
      evidence must be provided of the superiority of this patient management strategy with respect
      to standard clinical practice, based on routine in-office visits.

      Very recent findings showed that the use of CareLink in European clinical practice is
      technically feasible and that remote follow-up is an efficient method of surveillance of
      implanted patients. Moreover, the early detection and review of device and clinical events
      suggest the potential impact of remote monitoring on overall patient care.

      There are a number of possible limitations with remote monitoring. The CareLink Network
      system requires that the patient establishes an initial contact between the device and the
      remote monitor unit, and that the unit is properly hooked up to the phone line. Not all
      patients may be able to perform the setup properly. There may be a delay by the physician in
      consulting patient data (for example over weekends), with a risk of adverse events occurring
      during that interval. There may be difficulties in contacting patients (e.g. if they are
      traveling). These possible limitations need to be properly assessed, especially for
      monitoring atrial arrhythmias, where the time factor is of importance for avoiding
      complications.

      Remote patients' disease management has the potential for avoiding hospitalization. Clear
      demonstration that remote monitoring of AT/AF/HF plus strict treatment guidelines leads to a
      reduction in hospitalization rates has not been proven, and it could be a major argument for
      using this technology in routine clinical practice.

      The MORE-CARE Study is aimed at comparing two different strategies of disease management in
      heart failure patients treated with CRT-D devices:

        1. Remote disease management via Carelink Network system

        2. Standard disease management by means of scheduled routine in-patient follow-ups. The
           main objective of the study is to demonstrate that the remote management strategy is
           superior to the standard strategy, both in terms of clinical effectiveness and total
           healthcare system utilization.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment rate
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Median Time Between Event Onset Time and Clinical Decision for Each Subject.</measure>
    <time_frame>1 year since the randomization</time_frame>
    <description>The median delay from device-detected events to clinical decisions was considerably shorter in the Remote group compared to the Control group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Combined Endpoint of Death From Any Cause, Cardiovascular and Device-related Hospitalizations (at Least 48 Hours Stay), Calculated as Number of Subjects With at Least One Event</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>Time to first event</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">918</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic CareLink® Network</intervention_name>
    <description>Continuous monitoring via a disease remote management system.
Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient indicated to CRT-ICD according to current guidelines:

          -  Left ventricular systolic dysfunction (LVEF≤35%),

          -  New York Heart Association functional class III-IV,

          -  QRS≥120 ms

          -  Optimized medical treatment.

          -  Patient implanted within the last 8 weeks with Medtronic CRT-ICD device equipped with
             fluid accumulation diagnostics, AT/AF monitoring capability, wireless telemetry for
             automatic remote data transmission and alerting system for physician.

          -  Patient with less than 8 weeks follow-up, who has not received Carelink® Network
             Monitor and was not managed by Cardiac Compass report reviewing.

          -  Carelink Network is available at patient's home

          -  Patient or the patient's caregiver is willing and able to use the Medtronic CareLink®
             Network Monitor and to perform the required duties at home or has a family member or
             assistant perform those duties.

          -  Patient is willing and able to sign an informed consent form.

        Exclusion Criteria:

          -  Inability to fully understand the instructions relating to remote monitoring using
             CareLink® Network.

          -  Permanent AT/AF.

          -  Patient had not been previously implanted with a CRT/CRT-D device.

          -  Patient has medical conditions that would limit study participation.

          -  Patient is less than 18 years of age.

          -  Patient is enrolled in or intends to participate in another clinical trial that may
             have an impact on the study endpoints.

          -  Patient meets any exclusion criteria required by local law.

          -  Inability or refusal to sign a patient informed consent form.

          -  Patient's life expectancy is less than one year in the opinion of the physician

          -  Patient is pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haran Burri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Geneva Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Boriani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Universitario Sant'Orsola, Bologna, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renato Pietro Ricci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera San Filippo Neri, Roma, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aurelio Quesada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano Favale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Universitario di Bari, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josef Kautzner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IKEM, Prague, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine Da Costa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital du Nord, Saint Etienne, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Klinicke a Experimentalni Mediciny</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cardiologique du Haut Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Narbonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital La Source</name>
      <address>
        <city>Orleans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital La Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Bizet</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Nord</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evaggelismos Hospital</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Dynant Hospital - Athens</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Herakleion</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HYGEIA - Hospital</name>
      <address>
        <city>Marousi</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital AHEPA Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen György Országos Kardiológia Intézet GOKI</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University AOK</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Chioggia</city>
        <state>Venezia</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Mirano</city>
        <state>Venezia</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniche Gavazzeni</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale V.E. Ferrarotto</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pugliese e Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sant'Anna Hospital</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Unico della Versilia</name>
      <address>
        <city>Lido di Camaiore (LU)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Monaldi</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sacro Cuore Don Calabria</name>
      <address>
        <city>Negrar</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Giovan Battista Grassi</name>
      <address>
        <city>Ostia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica San Carlo</name>
      <address>
        <city>Paderno Dugnano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Civico e Benfratelli</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Fisiologia Clinica - CNR</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Complesso Ospedaliero San Filippo Neri</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Del Carmine</name>
      <address>
        <city>Rovereto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. di Trento P.O.S.Chiara</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera-Ospedali Riuniti</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale E. Macchi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Maggiore di Borgo Trento</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Haaglanden - Locatie Westeinde</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NUSCH</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUSCH</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De Torrevieja</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fé</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triemli Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Burri H, Quesada A, Ricci RP, Boriani G, Davinelli M, Favale S, Da Costa A, Kautzner J, Moser R, Navarro X, Santini M. The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) study: rationale and design. Am Heart J. 2010 Jul;160(1):42-8. doi: 10.1016/j.ahj.2010.04.005.</citation>
    <PMID>20598971</PMID>
  </reference>
  <results_reference>
    <citation>Boriani G, Da Costa A, Ricci RP, Quesada A, Favale S, Iacopino S, Romeo F, Risi A, Mangoni di S Stefano L, Navarro X, Biffi M, Santini M, Burri H; MORE-CARE Investigators. The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) randomized controlled trial: phase 1 results on dynamics of early intervention with remote monitoring. J Med Internet Res. 2013 Aug 21;15(8):e167. doi: 10.2196/jmir.2608.</citation>
    <PMID>23965236</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <results_first_submitted>November 23, 2016</results_first_submitted>
  <results_first_submitted_qc>February 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>918 patients have been enrolled in the study, from 29/05/2009 (date of first enrollment) until 20/08/2014 (date of last enrollment).</recruitment_details>
      <pre_assignment_details>918 subjects signed the Informed Consent Form. One of those subjects withdraw from the study prior randomization, therefore 917 subjects were randomized either to Study (462) or to Control (455) groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Group</title>
          <description>Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
Medtronic CareLink® Network: Continuous monitoring via a disease remote management system.
Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="462"/>
                <participants group_id="P2" count="455"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention To Treat</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
                <participants group_id="P2" count="428"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="279"/>
                <participants group_id="P2" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>premature study closure</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>device/lead revision or replacement</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Heart transplantation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/exclusion not met</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Group</title>
          <description>Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
Medtronic CareLink® Network: Continuous monitoring via a disease remote management system.
Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="437"/>
            <count group_id="B2" value="428"/>
            <count group_id="B3" value="865"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="11"/>
                    <measurement group_id="B2" value="67" spread="10"/>
                    <measurement group_id="B3" value="66" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="342"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of AF</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of AF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No History of AF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="340"/>
                    <measurement group_id="B2" value="361"/>
                    <measurement group_id="B3" value="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Myocardial Infarction</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With History of Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without History of Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LVEF</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="6.6"/>
                    <measurement group_id="B2" value="27.4" spread="6.0"/>
                    <measurement group_id="B3" value="27.3" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase 1: Median Time Between Event Onset Time and Clinical Decision for Each Subject.</title>
        <description>The median delay from device-detected events to clinical decisions was considerably shorter in the Remote group compared to the Control group</description>
        <time_frame>1 year since the randomization</time_frame>
        <population>Phase 1: A total of 154 patients were enrolled from May 2009 through April 2010 from 32 centers in 6 different countries (France, Hungary, Israel, Italy, Spain, and Switzerland). The final patient cohort object of analysis comprised 148 patients (76 in the Remote group and 72 in the Control group)</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
Medtronic CareLink® Network: Continuous monitoring via a disease remote management system.
Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Median Time Between Event Onset Time and Clinical Decision for Each Subject.</title>
          <description>The median delay from device-detected events to clinical decisions was considerably shorter in the Remote group compared to the Control group</description>
          <population>Phase 1: A total of 154 patients were enrolled from May 2009 through April 2010 from 32 centers in 6 different countries (France, Hungary, Israel, Italy, Spain, and Switzerland). The final patient cohort object of analysis comprised 148 patients (76 in the Remote group and 72 in the Control group)</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="29" lower_limit="3" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 2: Combined Endpoint of Death From Any Cause, Cardiovascular and Device-related Hospitalizations (at Least 48 Hours Stay), Calculated as Number of Subjects With at Least One Event</title>
        <description>Time to first event</description>
        <time_frame>2 years after randomization</time_frame>
        <population>All subjects in analysis were included in the primary endpoint analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
Medtronic CareLink® Network: Continuous monitoring via a disease remote management system.
Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Combined Endpoint of Death From Any Cause, Cardiovascular and Device-related Hospitalizations (at Least 48 Hours Stay), Calculated as Number of Subjects With at Least One Event</title>
          <description>Time to first event</description>
          <population>All subjects in analysis were included in the primary endpoint analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events have been collected since subject enrollment until subjct exit/death.</time_frame>
      <desc>The following Serious Adverse Events and Adverse Device Effects needed to be reported to Medtronic:
Serious Adverse Events (SAE);
Serious Adverse Device Effects (SADE);
Serious Adverse Procedure related Events (SAPE);
Unexpected Serious Adverse Effects (USAE). (Definition ISO EN ISO 14155-1)</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
          <description>Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
Medtronic CareLink® Network: Continuous monitoring via a disease remote management system.
Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemias nonhaemolytic and marrow depression</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis, stenosis, vascular insufficiency and necrosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="462"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Cardiac arrhythmias</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="462"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Cardiac disorder signs and symptoms</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="462"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Cardiac valve disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Coronary artery disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Heart failures</sub_title>
                <counts group_id="E1" events="132" subjects_affected="76" subjects_at_risk="462"/>
                <counts group_id="E2" events="133" subjects_affected="73" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Myocardial disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior eye structural change, deposit and degeneration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernias and other abdominal wall conditions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhages NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammatory conditions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility and defaecation conditions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Gastrointestinal signs and symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatal outcome</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="462"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>General system disorders NEC</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="462"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Tissue disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Tissue disorders NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections - pathogen unspecified</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bone and joint injuries</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Cardiac disorder signs and symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Injuries NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Medication errors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Procedural and device related injuries and complications NEC</sub_title>
                <counts group_id="E1" events="33" subjects_affected="32" subjects_at_risk="462"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac and vascular investigations (excl enzyme tests)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Gastrointestinal investigations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic complications</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Metabolism disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders NEC</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central nervous system vascular disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Increased intracranial pressure and hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Neurological disorders NEC</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Renal disorders (excl nephropathies)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Sleep disturbances (incl subtypes)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="462"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Ureteric disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Respiratory disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Respiratory tract infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Epidermal and dermal conditions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bone and joint therapeutic procedures</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Cardiac therapeutic procedures</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="462"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Head and neck therapeutic procedures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Renal and urinary tract therapeutic procedures</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Vascular therapeutic procedures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysms and artery dissections</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis, stenosis, vascular insufficiency and necrosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Vascular disorders NEC</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Vascular haemorrhagic disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemias nonhaemolytic and marrow depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis, stenosis, vascular insufficiency and necrosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Cardiac arrhythmias</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="462"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Cardiac disorder signs and symptoms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Coronary artery disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Heart failures</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="462"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Myocardial disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior eye structural change, deposit and degeneration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Infections - pathogen unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernias and other abdominal wall conditions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Gastrointestinal signs and symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device issues</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>General system disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bone and joint injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Injuries NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Procedural and device related injuries and complications NEC</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="462"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Cardiac disorder signs and symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac and vascular investigations (excl enzyme tests)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Gastrointestinal investigations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Metabolism disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Movement disorders (incl parkinsonism)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Neurological disorders NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Sleep disturbances (incl subtypes)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Ureteric disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infections</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Epidermal and dermal conditions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac therapeutic procedures</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Head and neck therapeutic procedures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Decreased and nonspecific blood pressure disorders and shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysms and artery dissections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
              </event>
              <event>
                <sub_title>Vascular disorders NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="455"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Valentina Amori</name_or_title>
      <organization>Medtronic EMEA RCC</organization>
      <phone>3425417863</phone>
      <email>valentina.amori@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

